MedPath

Correlative observational study of phase 1 study of RK-163 pulsed human autologous CD14-positive cells (RK-CD14MO) for patients with advanced or relapsed solid tumor

Not Applicable
Conditions
Advanced or relapsed solid tumor
Registration Number
JPRN-UMIN000032306
Lead Sponsor
Keio University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

Any patient that the PI/sub-PI deems ineligible to enroll in the study will be excluded from the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath